Merck Collaborated with Orna Therapeutics to Advance RNA Therapies for Infectious Disease and Oncology
- Orna to receive $150M up front & will be eligible to receive ~$3.5B in development, regulatory & sales milestones related to multiple vaccine and therapeutic programs along with royalties on any approved products that emerge from the collaboration. Merck will also invest $100M of equity in Orna’s completed series B financing round
- Orna holds the rights for its oRNA-LNP technology platform & continues to advance other programs in areas incl. oncology & genetic disease
- The collaboration will combine Merck’s expertise in nucleic acid biology, clinical development & manufacturing with Orna’s compelling circular RNA technology to develop multiple programs across infectious disease & oncology
Ref: Businesswire | Image: Merck
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.